Latest From iOnctura SA
IOnctura’s CEO Catherine Pickering outlines the company’s business model and its approach to cancer R&D targeting the tumor microenvironment.
Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
Complexa topped the list of recent venture capital financings with a $62m Series C round, followed by Evelo and Kezar with $50m Series B rounds and LogicBio with a $45m Series B.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Company Type
- Parent & Subsidiaries
- iOnctura SA
- Senior Management
Catherine Pickering, PhD, CEO
Lars van der Veen, PhD, COO
Zoë Johnson, CSO
Michael Lahn, CMO
- Contact Info
Campus Biotech Innov. Park, Bâtiment F2
Ave Sécheron 15
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.